Therefore, the effects of leptin on obesity-associated inflammation might be dose-dependent, and the management of obesity-associated diseases by using leptin as a potential therapeutic target requires careful consideration (42). This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.